Literature DB >> 17916983

Livedo reticularis as a criterion for antiphospholipid syndrome.

E Toubi1, Y Shoenfeld.   

Abstract

Many consensus meetings were organized in an attempt to improve the present criteria for antiphospholipid syndrome (APS) classification. In this regard, a high prevalence of antiphospholipid antibodies in systemic lupus erythematosus patients was reported in association with the presence of livedo reticularis (LR). In these studies, the association between LR, migraine, and the development of thrombosis (strokes, valvular dysfunctions) was evident. During the last decade, it was strongly suggested that many clinical symptoms (LR, valvular dysfunctions) or laboratory features (thrombocytopenia) should be considered as "minor criteria" for APS. The inclusion of these clinical symptoms in the criteria for APS classification could become of additive value especially when they exist together in one patient. This review summarizes the data that question or support this idea.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17916983     DOI: 10.1007/s12016-007-0004-0

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  38 in total

1.  Investigation and management of heritable thrombophilia.

Authors: 
Journal:  Br J Haematol       Date:  2001-09       Impact factor: 6.998

Review 2.  Antiphospholipid syndrome and recurrent miscarriages.

Authors:  D Vinatier; P Dufour; M Cosson; J L Houpeau
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2001-05       Impact factor: 2.435

3.  The association of thrombocytopenia with systemic manifestations in the antiphospholipid syndrome.

Authors:  Ilan Krause; Miri Blank; Abigail Fraser; Margalit Lorber; Ludmilla Stojanovich; Josef Rovensky; Yehuda Shoenfeld
Journal:  Immunobiology       Date:  2005-10-21       Impact factor: 3.144

4.  Livedo reticularis and pregnancy morbidity in patients negative for antiphospholipid antibodies.

Authors:  S Sangle; D P D'Cruz; G R V Hughes
Journal:  Ann Rheum Dis       Date:  2005-01       Impact factor: 19.103

5.  Validation of the Sapporo criteria for antiphospholipid syndrome.

Authors:  M D Lockshin; L R Sammaritano; S Schwartzman
Journal:  Arthritis Rheum       Date:  2000-02

6.  Anti-platelet antibodies in patients with systemic lupus erythematosus and the primary antiphospholipid antibody syndrome: their relationship with the observed thrombocytopenia.

Authors:  L Macchi; P Rispal; G Clofent-Sanchez; J L Pellegrin; P Nurden; B Leng; A T Nurden
Journal:  Br J Haematol       Date:  1997-08       Impact factor: 6.998

7.  Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages.

Authors:  Nicola Bizzaro; Elio Tonutti; Danilo Villalta; Marilina Tampoia; Renato Tozzoli
Journal:  Arch Pathol Lab Med       Date:  2005-01       Impact factor: 5.534

8.  Antiphospholipid antibody panels and recurrent pregnancy loss: prevalence of anticardiolipin antibodies compared with other antiphospholipid antibodies.

Authors:  D L Yetman; W H Kutteh
Journal:  Fertil Steril       Date:  1996-10       Impact factor: 7.329

9.  A comparison of cardiac valvular involvement in the primary antiphospholipid syndrome versus anticardiolipin-negative systemic lupus erythematosus.

Authors:  C B Gleason; M F Stoddard; S G Wagner; R A Longaker; S Pierangeli; E N Harris
Journal:  Am Heart J       Date:  1993-04       Impact factor: 4.749

10.  Anti-neutrophil cytoplasmic antibodies in 566 European patients with systemic lupus erythematosus: prevalence, clinical associations and correlation with other autoantibodies. European Concerted Action on the Immunogenetics of SLE.

Authors:  M Galeazzi; G Morozzi; G D Sebastiani; F Bellisai; R Marcolongo; R Cervera; E De Ramòn Garrido; A Fernandez-Nebro; F Houssiau; A Jedryka-Goral; A Mathieu; C Papasteriades; J C Piette; R Scorza; J Smolen
Journal:  Clin Exp Rheumatol       Date:  1998 Sep-Oct       Impact factor: 4.473

View more
  3 in total

1.  Cutting edge issues in autoimmunity.

Authors:  Yaniv Sherer; Torsten Matthias; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-06       Impact factor: 8.667

Review 2.  Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances.

Authors:  Savino Sciascia; Mary-Carmen Amigo; Dario Roccatello; Munther Khamashta
Journal:  Nat Rev Rheumatol       Date:  2017-08-03       Impact factor: 20.543

3.  Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index.

Authors:  Sherif Gamal; Samar Mohamed; Abdelkawy Moghazy
Journal:  Arch Rheumatol       Date:  2022-01-23       Impact factor: 1.007

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.